HRP20201285T1 - Reagensi sirp-alfa visokog afiniteta - Google Patents
Reagensi sirp-alfa visokog afiniteta Download PDFInfo
- Publication number
- HRP20201285T1 HRP20201285T1 HRP20201285TT HRP20201285T HRP20201285T1 HR P20201285 T1 HRP20201285 T1 HR P20201285T1 HR P20201285T T HRP20201285T T HR P20201285TT HR P20201285 T HRP20201285 T HR P20201285T HR P20201285 T1 HRP20201285 T1 HR P20201285T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- sirpα
- affinity
- amino acid
- polypeptide according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03048—Protein-tyrosine-phosphatase (3.1.3.48)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (25)
1. Polipeptid SIRPα visokog afiniteta, naznačen time, da sadrži najmanje jednu i ne više od 15 aminokiselinskih modifikacija unutar d1 domene ljudske sekvence SIRPα divljeg tipa, pri čemu su modifikacije učinjene na ostacima koji odgovaraju ostacima odabranima iz skupine koja se sastoji od sljedećih: L4, V6, A21, V27, I31, E47, K53, E54, H56, V63, S66, K68, V92, F94 i F103 od SEQ ID NO:1, gdje aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47 u odnosu na afinitet ljudskog polipeptida SIRPα divljeg tipa i pritom polipeptidu SIRPα visokog afiniteta nedostaje domena transmembrane SIRPα.
2. Polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid SIRPα visokog afiniteta ima KD od najmanje 1 x 10-9 M za CD47.
3. Polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid SIRPα visokog afiniteta ima KD od najmanje 1 x 10-8 M za CD47.
4. Polipeptid prema bio kojem od patentnih zahtjeva 1 do 3, naznačen time, da
(i) se polipeptid sastoji od cijele ili od dijela d1 domene SIRPα, i
(ii) polipeptid sadrži aminokiselinske sekvence od SIRPα izvan d1 domene.
5. Polipeptid prema patentnom zahtjevu 1, naznačen time, da sadrži najmanje jednu aminokiselinsku modifikaciju odabranu od sljedećih: (1) L4V; L4I; (2) V6I; V6L; (3) A21V; (4) V27I; V27L; (5) I31T; I31S; I31F; (6) E47V; E47L; (7) K53R; (8) E54Q; (9) H56P; H56R; (10) S66T; S66G; (11) K68R; (12)V92I; (13) F94L; F94V; (14) V63I; i (15) F103V.
6. Polipeptid prema patentnom zahtjevu 5, naznačen time, da sadrži aminokiselinske modifikacije odabrane od sljedećih:
i. V6I; V27I; I31F; E47V; K53R; E54Q; H56P; S66T; i V92I;
ii. V27I ili V27L; K53R; S66T ili S66G; K68R; i F103V;
iii. L4V ili L4I; V27I ili V27L; E47V ili E47L; K53R; E54Q; S66T ili S66G; K68R; V92I; i F103V;
iv. L4V ili L4I; V6I ili V6L; A21V; V27I ili V27L; I31T, I31S ili I31F; E47V ili E47L; K53R; H56P ili H56R; S66T ili S66G; K68R; i F94L ili F94V;
v. V6I ili V6L; V27I ili V27L; I31T, I31S ili I31F; E47V ili E47L; K53R; E54Q; H56P ili H56R; S66T ili S66G; V92I; i F94L ili F94V;
vi. L4V ili L4I; A21V; V27I ili V27L; I31T, I31S ili I31F; E47V ili E47L; K53R; E54Q; H56P ili H56R; S66T ili S66G; F94L ili F94V; i F103V;
vii. L4V ili L4I; V6I ili V6L; V27I ili V27L; I31T, I31S ili I31F; E47V ili E47L; K53R; H56P ili H56R; S66T ili S66G; K68R; V92I, i F94L ili F94V;
viii. L4V ili L4I; V6I ili V6L; I31T, I31S ili I31F; E47V ili E47L; K53R; H56P ili H56R; S66T ili S66G; V92I; i F103V;
ix. V6I; V27I; I31F; E47L; K53R; E54Q; H56P; i S66T;
x. L4V; V6I; V27I; I31F; E47V; K53R; E54Q; H56P; V63I; S66T; K68R; i V92I;
xi. V6I; V27I; I31T; E47V; K53R; E54Q; H56P; S66G; K68R; V92I; i F103V;
xii. V27I; K53R; S66T; S66G; K68R; F103V;
xiii. L4V; V27L; E47V; K53R; E54Q; S66G; K68R; V92I;
xiv. L4V; V6I; A21V; V27I; I31T; E47L; K53R; H56P; S66T; K68R; F94L;
xv. V6I; V27I; I31S; I31F; E47V; K53R; E54Q; H56P; S66G; V92I; F94L;
xvi. L4I; A21V; V27I; I31F; E47V; K53R; E54Q; H56R; S66G; F94V; F103V;
xvii. L4V; V6I; V27I; I31F; E47V; K53R; H56R; S66G; K68R; V92I; F94L; ili
xviii. L4V; V6L; I31F; E47V; K53R; H56P; S66G; V92I; F103V.
7. Polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid SIRPα visokog afiniteta sadrži aminokiselinsku sekvencu prikazanu u bilo kojem od SEQ ID NO: 3-6, 8-10 i 37-39.
8. Polipeptid prema patentnom zahtjevu 1, naznačen time, da polipeptid sadrži aminokiselinsku sekvencu prikazanu u SEQ ID NO: 10.
9. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 8, naznačen time, da je staljen na Fc sekvencu imunoglobulina.
10. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da je polipeptid SIRPα visokog afiniteta multimer.
11. Terapeutska formulacija, naznačena time, da obuhvaća polipeptid u skladu s bilo kojim od patentnih zahtjeva 1 do 10.
12. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 10, naznačen time, da polipeptid dodatno sadrži oznaku koja se može detektirati.
13. Formulacija prema patentnom zahtjevu 11, naznačena time, da se upotrebljava u postupku liječenja raka, pri čemu postupak obuhvaća dovođenje u doticaj in vivo stanice koja eksprimira CD47 s formulacijom.
14. Formulacija za uporabu prema patentnom zahtjevu 13, naznačena time, da nadalje obuhvaća dovođenje u doticaj navedene stanice s protutijelom koje je specifično za tumor.
15. Formulacija za uporabu prema patentnom zahtjevu 13, naznačena time, da stanica koja eksprimira CD47 jest stanica raka.
16. Formulacija prema patentnom zahtjevu 11, naznačena time, da se upotrebljava u postupku liječenja upalne bolesti ili autoimune bolesti, pri čemu postupak obuhvaća davanje formulacije u spoju s terapeutskim protutijelom.
17. Postupak in vitro za modulaciju fagocitoze stanice koja eksprimira CD47, naznačen time, da obuhvaća dovođenje u doticaj in vitro navedene stanice s formulacijom u skladu s patentnim zahtjevom 11.
18. Polipeptid prema patentnom zahtjevu 12, naznačen time, da se upotrebljava u postupku prikazivanja tumora, pri čemu postupak obuhvaća dovođenje u doticaj stanica raka s polipeptidom.
19. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 9, naznačen time, da je polipeptid SIRPα visokog afiniteta monomer.
20. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 10 puta.
21. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 20 puta.
22. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 50 puta.
23. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 100 puta.
24. Polipeptid prema patentnom zahtjevu 1, naznačen time, da aminokiselinska modifikacija povećava afinitet polipeptida SIRPα koji se veže na CD47, pomoću smanjivanja brzine odvajanja, barem 500 puta.
25. Polipeptid prema bilo kojem od patentnih zahtjeva 1 do 14, naznačen time, da CD47 je ljudski CD47.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261587247P | 2012-01-17 | 2012-01-17 | |
| PCT/US2013/021937 WO2013109752A1 (en) | 2012-01-17 | 2013-01-17 | High affinity sirp-alpha reagents |
| EP13738232.1A EP2804617B9 (en) | 2012-01-17 | 2013-01-17 | High affinity sirp-alpha reagents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20201285T1 true HRP20201285T1 (hr) | 2020-11-13 |
Family
ID=48799653
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20201285TT HRP20201285T1 (hr) | 2012-01-17 | 2013-01-17 | Reagensi sirp-alfa visokog afiniteta |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US9944911B2 (hr) |
| EP (2) | EP2804617B9 (hr) |
| JP (5) | JP6460796B2 (hr) |
| CN (2) | CN104136037B (hr) |
| AU (1) | AU2013209736C1 (hr) |
| CA (1) | CA2861307C (hr) |
| CY (1) | CY1123419T1 (hr) |
| DK (1) | DK2804617T3 (hr) |
| ES (1) | ES2816647T3 (hr) |
| HK (1) | HK1253217A1 (hr) |
| HR (1) | HRP20201285T1 (hr) |
| HU (1) | HUE050875T2 (hr) |
| LT (1) | LT2804617T (hr) |
| PL (1) | PL2804617T3 (hr) |
| PT (1) | PT2804617T (hr) |
| RS (1) | RS60606B1 (hr) |
| SI (1) | SI2804617T1 (hr) |
| SM (1) | SMT202000689T1 (hr) |
| WO (1) | WO2013109752A1 (hr) |
Families Citing this family (140)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104136037B (zh) * | 2012-01-17 | 2018-02-23 | 小利兰·斯坦福大学托管委员会 | 高亲和力SIRP‑α试剂 |
| PL2812443T3 (pl) | 2012-02-06 | 2020-01-31 | Inhibrx, Inc. | Przeciwciała CD47 i sposoby ich zastosowania |
| SMT201900623T1 (it) * | 2012-12-17 | 2020-01-14 | Trillium Therapeutics Inc | Trattamento di cellule di malattia cd47+ con fusioni sirp alpha-fc |
| CN114917336A (zh) * | 2013-03-15 | 2022-08-19 | 小利兰·斯坦福大学托管委员会 | 用于实现治疗有效剂量的抗cd47剂的方法 |
| US10064925B2 (en) | 2013-04-29 | 2018-09-04 | The Board Of Trustees Of The Leland Stanford Junior University | Use of anti-CD47 agents to enhance immunization |
| US10329354B2 (en) | 2013-09-18 | 2019-06-25 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of efferocytosis pathways for treatment of atherosclerotic disease |
| EP3131917B1 (en) | 2014-04-18 | 2020-06-17 | The Board of Trustees of the Leland Stanford Junior University | Humanized and chimeric monoclonal antibodies to cd99 |
| CA2994927A1 (en) | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity pd-1 agents and methods of use |
| WO2016023001A1 (en) * | 2014-08-08 | 2016-02-11 | The Board Of Trustees Of The Leland Stanford Junior University | Multispecific high affinity pd-1 agents and methods of use |
| US10087257B2 (en) | 2014-08-08 | 2018-10-02 | The Board Of Trustees Of The Leland Stanford Junior University | SIRP alpha-antibody fusion proteins |
| CN113621075B (zh) * | 2014-08-08 | 2024-09-20 | Alx肿瘤生物技术公司 | SIRP-α变体构建体及其用途 |
| WO2016024021A1 (en) | 2014-08-15 | 2016-02-18 | Merck Patent Gmbh | Sirp-alpha immunoglobulin fusion proteins |
| DK3656869T4 (da) | 2014-08-26 | 2025-05-19 | Univ Leland Stanford Junior | Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering |
| EP3194024B1 (en) * | 2014-09-15 | 2020-08-05 | The Board of Trustees of the Leland Stanford Junior University | Targeting aneurysm disease by modulating phagocytosis pathways |
| WO2016065329A1 (en) | 2014-10-24 | 2016-04-28 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for inducing phagocytosis of mhc class i positive cells and countering anti-cd47/sirpa resistance |
| EP3012271A1 (en) | 2014-10-24 | 2016-04-27 | Effimune | Method and compositions for inducing differentiation of myeloid derived suppressor cell to treat cancer and infectious diseases |
| AU2015350190B2 (en) * | 2014-11-18 | 2021-08-05 | Janssen Pharmaceutica Nv | CD47 antibodies, methods, and uses |
| CA2972604C (en) * | 2014-12-30 | 2023-07-04 | Celgene Corporation | Anti-cd47 antibodies and uses thereof |
| EP3261671B1 (en) | 2015-02-27 | 2020-10-21 | The Board of Trustees of the Leland Stanford Junior University | Combination therapy for treatment of atherosclerosis |
| CN106146670B (zh) * | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术（上海）有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
| WO2016179399A1 (en) * | 2015-05-06 | 2016-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | High affinity cd47 analogs |
| CA2994935A1 (en) * | 2015-05-18 | 2016-11-24 | Ab Initio Biotherapeutics, Inc. | Sirp polypeptide compositions and methods of use |
| EA034582B1 (ru) * | 2015-08-07 | 2020-02-21 | АЭлЭкс ОНКОЛОДЖИ ИНК. | Конструкции варианта sirp-альфа и их применение |
| IL302491A (en) | 2015-08-07 | 2023-06-01 | Alx Oncology Inc | Constructs having a sirp-alpha domain or variant thereof |
| AU2016310348B2 (en) | 2015-08-26 | 2023-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist |
| WO2017100462A2 (en) | 2015-12-11 | 2017-06-15 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of cancer with dual targeting of cd47 and egfr |
| KR102472087B1 (ko) | 2016-01-11 | 2022-11-29 | 포티 세븐, 인코포레이티드 | 인간화된, 마우스 또는 키메라 항-cd47 단클론 항체 |
| UA126658C2 (uk) | 2016-04-14 | 2023-01-11 | Осе Іммьюнотерапьютікс | НОВІ АНТИТІЛА ДО SIRPa ТА ВАРІАНТИ ЇХ ТЕРАПЕВТИЧНОГО ЗАСТОСУВАННЯ |
| SI3442578T1 (sl) | 2016-04-15 | 2022-05-31 | The Board Of Trustees Of The Leland Standford Junior University | Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka |
| WO2017184553A1 (en) * | 2016-04-18 | 2017-10-26 | Baylor College Of Medicine | Cancer gene therapy targeting cd47 |
| CA3019841A1 (en) * | 2016-04-29 | 2017-11-02 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for the prevention and treatment of surgical adhesions |
| US11560433B2 (en) | 2016-05-27 | 2023-01-24 | Albert Einstein College Of Medicine | Methods of treatment by targeting VCAM1 and MAEA |
| US10148939B2 (en) | 2016-07-19 | 2018-12-04 | Gopro, Inc. | Mapping of spherical image data into rectangular faces for transport and decoding across networks |
| EP3532497B1 (en) * | 2016-10-26 | 2024-07-24 | The Board of Trustees of the Leland Stanford Junior University | Modified immunoglobulin hinge regions to reduce hemagglutination |
| WO2018081898A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Improvements in cd47 blockade therapy by hdac inhibitors |
| WO2018081897A1 (en) | 2016-11-03 | 2018-05-11 | Trillium Therapeutics Inc. | Enhancement of cd47 blockade therapy by proteasome inhibitors |
| KR102129067B1 (ko) * | 2016-12-29 | 2020-07-08 | 한국과학기술연구원 | 신규 엑소좀 계열 항암제 |
| CA3047708A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A sirpalpha-41bbl fusion protein and methods of use thereof |
| WO2018127916A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-cd70 fusion protein and methods of use thereof |
| CA3047707A1 (en) | 2017-01-05 | 2018-07-12 | Kahr Medical Ltd. | A pd1-41bbl fusion protein and methods of use thereof |
| AU2018205276A1 (en) | 2017-01-06 | 2019-07-18 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| BR112019015342A2 (pt) | 2017-01-30 | 2020-03-10 | The Board Of Trustees Of The Leland Stanford Junior University | Regime de condicionamento não genotóxico para o transplante de células-tronco |
| WO2018160739A1 (en) | 2017-02-28 | 2018-09-07 | The Board Of Trustees Of The Leland Stanford Junior University | Antifibrotic activity of cd47 blockade |
| WO2018165015A1 (en) | 2017-03-09 | 2018-09-13 | The Board Of Trustees Of The Leland Stanford Junior University | Treatment of pediatric brain tumors with targeting of cd47 pathway |
| WO2018237168A1 (en) | 2017-06-21 | 2018-12-27 | The Board Of Trustees Of The Leland Stanford Junior University | DOSING PARAMETERS FOR CD47 TARGETING THERAPIES WITH HEMATOLOGICAL MALIGNANCIES |
| AU2018301668A1 (en) | 2017-07-12 | 2019-12-19 | Synlogic Operating Company, Inc. | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells |
| MX2020001309A (es) | 2017-08-02 | 2020-08-20 | Phanes Therapeutics Inc | Anticuerpos anti-cd47 y sus usos. |
| CN111051350B (zh) * | 2017-09-07 | 2022-11-01 | 苏州丁孚靶点生物技术有限公司 | 包含信号调节蛋白α的免疫缀合物 |
| WO2019061012A1 (zh) * | 2017-09-26 | 2019-04-04 | 南京凯地生物科技有限公司 | 靶向cd47的特异性嵌合抗原受体t细胞的制备及其应用 |
| US11713356B2 (en) | 2017-10-13 | 2023-08-01 | Ose Immunotherapeutics | Modified bifunctional anti-human signal regulatory protein alpha (SIRPa) antibody and method of use thereof for treating cancer |
| CA3078253A1 (en) | 2017-10-18 | 2019-04-25 | Forty Seven, Inc. | Anti-cd47 agent-based ovarian cancer therapy |
| CA3080640C (en) | 2017-11-06 | 2024-04-09 | Trillium Therapeutics Inc. | Cd47 blockade with radiation therapy |
| MA51208A (fr) * | 2017-12-01 | 2020-10-07 | Seattle Genetics Inc | Anticorps (masqués) contre cd47 et leurs utilisations pour le traîtement du cancer |
| JP6961090B2 (ja) * | 2017-12-08 | 2021-11-05 | ハンクス バイオファーマシューティクス，インコーポレイテッド | 抗ｐｄ−１／ｃｄ４７二重特異性抗体及びその適用 |
| CN109971716B (zh) * | 2017-12-28 | 2023-08-01 | 上海细胞治疗研究院 | 自分泌cd47抗体的egfr特异性car-t细胞及其用途 |
| US11891450B2 (en) | 2018-02-12 | 2024-02-06 | Forty Seven, Inc. | Anti-CD47 agent-based treatment of CD20-positive cancer |
| CN108484774B (zh) * | 2018-03-09 | 2021-11-05 | 上海高菲生物科技有限公司 | 一种SIRPα融合蛋白及其制备方法和用途 |
| KR20210006338A (ko) | 2018-03-13 | 2021-01-18 | 오제 이뮈노테라프틱스 | 항-인간 SIRPa v1 항체의 이용 및 항-SIRPa v1 항체를 생산하는 방법 |
| JP2021515779A (ja) * | 2018-03-13 | 2021-06-24 | トリリアム・セラピューティクス・インコーポレイテッドＴｒｉｌｌｉｕｍ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． | Ｅｇｆｒ抗体によるｃｄ４７遮断療法における改善 |
| CN108872569A (zh) * | 2018-06-19 | 2018-11-23 | 浠思（上海）生物技术有限公司 | 利用HTRF一步法筛选CD47/SIRP alpha阻断剂的方法 |
| KR20250079073A (ko) | 2018-07-10 | 2025-06-04 | 고쿠리츠다이가쿠호진 고베다이가쿠 | 항 SIRPα 항체 |
| WO2020012486A1 (en) | 2018-07-11 | 2020-01-16 | Kahr Medical Ltd. | SIRPalpha-4-1BBL VARIANT FUSION PROTEIN AND METHODS OF USE THEREOF |
| AU2019301315A1 (en) | 2018-07-11 | 2021-02-11 | Kahr Medical Ltd. | PD1-4-1BBL variant fusion protein and methods of use thereof |
| KR102129522B1 (ko) * | 2018-07-26 | 2020-07-02 | 한국과학기술연구원 | 암세포 특이적 항암 단백질-형광 복합체 및 이를 포함하는 암의 진단 및 영상화용 조성물 |
| EP3843772A2 (en) | 2018-08-31 | 2021-07-07 | ALX Oncology Inc. | Decoy polypeptides |
| CA3111323A1 (en) | 2018-09-04 | 2020-03-12 | Trillium Therapeutics Inc. | Cd47 blockade with parp inhibition for disease treatment |
| CN109306017B (zh) * | 2018-10-12 | 2021-02-09 | 倍而达药业（苏州）有限公司 | 一种基于SIRP-αD1突变体制备的重组蛋白及应用 |
| EP3878469A4 (en) * | 2018-11-07 | 2022-08-03 | Daiichi Sankyo Company, Limited | METHOD FOR IMPROVING THE KINETICS OF A PEPTIDE IN BLOOD |
| CN111303293B (zh) | 2018-11-14 | 2022-08-30 | 杭州尚健生物技术有限公司 | 一种融合蛋白及其用途 |
| CN113166727A (zh) | 2018-11-28 | 2021-07-23 | 四十七公司 | 对消融方案耐受的基因修饰的hspc |
| CA3121273A1 (en) * | 2018-11-29 | 2020-06-04 | Trillium Therapeutics Inc. | Biomarkers for cd47 blockade therapy |
| EP3898676A1 (en) | 2018-12-21 | 2021-10-27 | OSE Immunotherapeutics | Bifunctional anti-pd-1/sirpa molecule |
| CA3141130A1 (en) | 2019-05-31 | 2020-12-03 | ALX Oncology Inc. | Methods of treating cancer with sirp alpha fc fusion in combination with an immune checkpoint inhibitor |
| JP7561775B2 (ja) | 2019-06-07 | 2024-10-04 | エーエルエックス オンコロジー インコーポレイテッド | 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬 |
| WO2020257196A1 (en) * | 2019-06-17 | 2020-12-24 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of treating infections by blocking pathogen mimics of cd47 |
| EP3999107A1 (en) | 2019-07-16 | 2022-05-25 | Gilead Sciences, Inc. | Hiv vaccines and methods of making and using |
| PL4045083T3 (pl) | 2019-10-18 | 2024-05-13 | Forty Seven, Inc. | Terapie skojarzone do leczenia zespołów mielodysplastycznych i ostrej białaczki szpikowej |
| EP4052040A1 (en) | 2019-10-31 | 2022-09-07 | Forty Seven, Inc. | Anti-cd47 and anti-cd20 based treatment of blood cancer |
| WO2021108693A1 (en) | 2019-11-27 | 2021-06-03 | ALX Oncology Inc. | Combination therapies for treating cancer |
| SI4081305T1 (sl) | 2019-12-24 | 2025-03-31 | Carna Biosciences, Inc. | Spojine, ki modulirajo diacilglicerol kinazo |
| CN115087488A (zh) | 2020-02-14 | 2022-09-20 | 震动疗法股份有限公司 | 与ccr8结合的抗体和融合蛋白及其用途 |
| WO2021191870A1 (en) | 2020-03-27 | 2021-09-30 | Dcprime B.V. | Ex vivo use of modified cells of leukemic origin for enhancing the efficacy of adoptive cell therapy |
| US12343377B2 (en) | 2020-06-01 | 2025-07-01 | ALX Oncology Inc. | Combination therapies comprising a hypomethylation agent for treating cancer |
| WO2022010806A1 (en) | 2020-07-06 | 2022-01-13 | ALX Oncology Inc. | Methods for reducing the interference of drugs that bind therapeutic targets expressed on blood cells in serological assays |
| CN114057888A (zh) * | 2020-07-30 | 2022-02-18 | 三生国健药业（上海）股份有限公司 | 一种SIRPα-Fc融合蛋白 |
| JP7446953B2 (ja) * | 2020-08-27 | 2024-03-11 | 株式会社三共 | 遊技機 |
| KR102557016B1 (ko) * | 2020-09-22 | 2023-07-20 | 비피진 주식회사 | 암 치료를 위한 cd47 바인더 및 리포좀 복합체 |
| TWI815194B (zh) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | 介白素2-Fc融合蛋白及使用方法 |
| US20220196651A1 (en) | 2020-12-06 | 2022-06-23 | ALX Oncology Inc. | Multimers for reducing the interference of drugs that bind cd47 in serological assays |
| WO2022190058A1 (en) | 2021-03-12 | 2022-09-15 | Dcprime B.V. | Methods of vaccination and use of cd47 blockade |
| TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | ＣＤ４７／ＳＩＲＰα結合及ＮＥＤＤ８活化酶Ｅ１調節次單元之共抑制以用於治療癌症 |
| CA3217814A1 (en) | 2021-04-27 | 2022-11-03 | Pfizer Inc. | Enhancement of cd47 blockade therapy with dhfr inhibitors |
| CA3216908A1 (en) | 2021-05-13 | 2022-11-17 | ALX Oncology Inc. | Combination therapies for treating cancer |
| US11932634B2 (en) | 2021-06-23 | 2024-03-19 | Gilead Sciences, Inc. | Diacylglycerol kinase modulating compounds |
| CN117396478A (zh) | 2021-06-23 | 2024-01-12 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| KR20240023628A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| KR20240023629A (ko) | 2021-06-23 | 2024-02-22 | 길리애드 사이언시즈, 인코포레이티드 | 디아실글리세롤 키나제 조절 화합물 |
| KR20230016152A (ko) * | 2021-07-19 | 2023-02-01 | 주식회사유한양행 | Sirp-alpha 변이체 및 이의 용도 |
| US20230183216A1 (en) | 2021-10-28 | 2023-06-15 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
| WO2023073580A1 (en) | 2021-10-29 | 2023-05-04 | Pfizer Inc. | Enhancement of cd47 blockade with taxanes for cd47+ cancer therapy |
| CR20240173A (es) | 2021-10-29 | 2024-06-20 | Gilead Sciences Inc | Compuestos de cd73 |
| CN118139874A (zh) * | 2021-11-01 | 2024-06-04 | 山东先声生物制药有限公司 | SIRPa突变体及其应用 |
| WO2023079438A1 (en) | 2021-11-08 | 2023-05-11 | Pfizer Inc. | Enhancement of cd47 blockade therapy with anti-vegf agents |
| WO2023107954A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| US20230203202A1 (en) | 2021-12-08 | 2023-06-29 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
| CN117597141A (zh) * | 2021-12-21 | 2024-02-23 | Fbd生物制品有限公司 | 工程改造的SIRPα变体及其使用方法 |
| WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| EP4452414A2 (en) | 2021-12-22 | 2024-10-30 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| WO2023121890A1 (en) * | 2021-12-23 | 2023-06-29 | Fbd Biologics Limited | Cd47/4-1bb-targeting protein complex and methods of use thereof |
| IL314210A (en) * | 2022-01-18 | 2024-09-01 | Fbd Biologics Ltd | CD47/PD-L1-targeted protein complex and methods of using it |
| TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Ｐａｒｐ７抑制劑 |
| WO2023154578A1 (en) | 2022-02-14 | 2023-08-17 | Sana Biotechnology, Inc. | Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells |
| HUE069263T2 (hu) | 2022-03-17 | 2025-02-28 | Gilead Sciences Inc | Ikarosz cink-ujj család degradálói és azok alkalmazása |
| WO2023183313A1 (en) | 2022-03-22 | 2023-09-28 | Sana Biotechnology, Inc. | Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods |
| CN119546769A (zh) | 2022-03-24 | 2025-02-28 | 比特根生物股份公司 | 具有修饰的FC结构域的SIRP-α融合多肽 |
| WO2023183890A1 (en) | 2022-03-24 | 2023-09-28 | Bitterroot Bio, Inc. | Multivalent sirp-alpha fusion polypeptides |
| US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| TWI876305B (zh) | 2022-04-05 | 2025-03-11 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
| IL316058A (en) | 2022-04-21 | 2024-11-01 | Gilead Sciences Inc | Compounds modulate KRAS G12D |
| WO2023228044A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Dosing regimens of sirp alpha fusion proteins for treatment of cancer |
| WO2023235754A1 (en) | 2022-06-01 | 2023-12-07 | ALX Oncology Inc. | Combination therapies for treating urothelial carcinoma |
| IL317958A (en) | 2022-07-01 | 2025-02-01 | Gilead Sciences Inc | CD73 compounds |
| EP4554628A1 (en) | 2022-07-12 | 2025-05-21 | Gilead Sciences, Inc. | Hiv immunogenic polypeptides and vaccines and uses thereof |
| WO2024015634A2 (en) * | 2022-07-15 | 2024-01-18 | Nutcracker Therapeutics, Inc. | Mrna therapies including sirp-alpha |
| WO2024040151A1 (en) | 2022-08-18 | 2024-02-22 | Pfizer Inc. | Sirp alpha fusion protein and anti-cd38 antibody combination therapies |
| WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
| WO2024121777A1 (en) | 2022-12-09 | 2024-06-13 | Pfizer Inc. | Cd47 blocking agent and anti-bcma / anti-cd3 bispecific antibody combination therapy |
| TW202440151A (zh) | 2022-12-09 | 2024-10-16 | 美商輝瑞大藥廠 | Ｃｄ４７阻斷劑及抗ｃｄ２０／抗ｃｄ３雙特異性抗體組合療法 |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2024193635A1 (en) * | 2023-03-22 | 2024-09-26 | Wangzhi LI | Sirp variants and uses thereof |
| WO2024215754A1 (en) | 2023-04-11 | 2024-10-17 | Gilead Sciences, Inc. | Kras modulating compounds |
| WO2024220917A1 (en) | 2023-04-21 | 2024-10-24 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024245380A1 (en) * | 2023-05-31 | 2024-12-05 | Fbd Biologics Limited | Cd47/pd-l1-targeting protein complex and methods of use thereof |
| WO2025006720A1 (en) | 2023-06-30 | 2025-01-02 | Gilead Sciences, Inc. | Kras modulating compounds |
| US20250066328A1 (en) | 2023-07-26 | 2025-02-27 | Gilead Sciences, Inc. | Parp7 inhibitors |
| WO2025024811A1 (en) | 2023-07-26 | 2025-01-30 | Gilead Sciences, Inc. | Parp7 inhibitors |
| US20250101042A1 (en) | 2023-09-08 | 2025-03-27 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
| WO2025054530A1 (en) | 2023-09-08 | 2025-03-13 | Gilead Sciences, Inc. | Pyrimidine-containing polycyclic derivatives as kras g12d modulating compounds |
| WO2025096589A1 (en) | 2023-11-03 | 2025-05-08 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6541615B1 (en) * | 1996-11-15 | 2003-04-01 | Max-Planck-Gellschaft Zur Foderung Der Wissenschaften E.V. | SIRP proteins and uses thereof |
| EP1192176A4 (en) * | 1999-06-11 | 2003-03-05 | Human Genome Sciences Inc | 49 HUMAN SECRETED PROTEINS |
| WO2005019254A1 (en) * | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of a bilin-binding protein with affinity for a given target |
| US8377448B2 (en) * | 2006-05-15 | 2013-02-19 | The Board Of Trustees Of The Leland Standford Junior University | CD47 related compositions and methods for treating immunological diseases and disorders |
| WO2009046541A1 (en) | 2007-10-11 | 2009-04-16 | University Health Network | MODULATION OF SIRPα - CD47 INTERACTION FOR INCREASING HUMAN HEMATOPOIETIC STEM CELL ENGRAFTMENT AND COMPOUNDS THEREFOR |
| KR20110112299A (ko) * | 2008-12-19 | 2011-10-12 | 노파르티스 아게 | 자가면역 및 염증성 장애의 치료에 사용하기 위한 가용성 폴리펩티드 |
| HRP20150553T1 (hr) * | 2009-05-15 | 2015-08-28 | University Health Network | Sastavi i metode za lijeäśenje hematoloških maligniteta ciljajuä†i sirp - cd47 interakciju |
| CN104136037B (zh) * | 2012-01-17 | 2018-02-23 | 小利兰·斯坦福大学托管委员会 | 高亲和力SIRP‑α试剂 |
| DK3656869T4 (da) * | 2014-08-26 | 2025-05-19 | Univ Leland Stanford Junior | Transplantation af stamceller med en kombination af et stof, som er rettet mod stamceller, og modulation af immunregulatorisk signalering |
| AU2016310348B2 (en) * | 2015-08-26 | 2023-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Enhanced depletion of targeted cells with CD47 blockade and an immune costimulatory agonist |
| KR102024554B1 (ko) * | 2018-02-26 | 2019-09-24 | 엘지전자 주식회사 | 유도 가열 장치 및 유도 가열 장치의 제어 방법 |
-
2013
- 2013-01-17 CN CN201380010007.5A patent/CN104136037B/zh active Active
- 2013-01-17 HR HRP20201285TT patent/HRP20201285T1/hr unknown
- 2013-01-17 RS RS20200928A patent/RS60606B1/sr unknown
- 2013-01-17 CA CA2861307A patent/CA2861307C/en active Active
- 2013-01-17 EP EP13738232.1A patent/EP2804617B9/en active Active
- 2013-01-17 CN CN201711161230.6A patent/CN107880100A/zh active Pending
- 2013-01-17 JP JP2014552401A patent/JP6460796B2/ja active Active
- 2013-01-17 LT LTEP13738232.1T patent/LT2804617T/lt unknown
- 2013-01-17 ES ES13738232T patent/ES2816647T3/es active Active
- 2013-01-17 EP EP20180952.2A patent/EP3766511A1/en active Pending
- 2013-01-17 PT PT137382321T patent/PT2804617T/pt unknown
- 2013-01-17 SM SM20200689T patent/SMT202000689T1/it unknown
- 2013-01-17 HU HUE13738232A patent/HUE050875T2/hu unknown
- 2013-01-17 SI SI201331779T patent/SI2804617T1/sl unknown
- 2013-01-17 PL PL13738232T patent/PL2804617T3/pl unknown
- 2013-01-17 US US14/371,370 patent/US9944911B2/en active Active
- 2013-01-17 WO PCT/US2013/021937 patent/WO2013109752A1/en active Application Filing
- 2013-01-17 DK DK13738232.1T patent/DK2804617T3/da active
- 2013-01-17 AU AU2013209736A patent/AU2013209736C1/en active Active
-
2015
- 2015-03-10 HK HK18112498.2A patent/HK1253217A1/zh unknown
-
2017
- 2017-07-10 JP JP2017134728A patent/JP6742279B2/ja active Active
-
2018
- 2018-03-05 US US15/912,471 patent/US11208481B2/en active Active
-
2019
- 2019-08-22 JP JP2019151758A patent/JP6783361B2/ja active Active
-
2020
- 2020-05-13 JP JP2020084303A patent/JP6918179B2/ja active Active
- 2020-08-27 CY CY20201100807T patent/CY1123419T1/el unknown
-
2021
- 2021-07-20 JP JP2021119529A patent/JP2021176873A/ja not_active Withdrawn
- 2021-11-18 US US17/530,287 patent/US12195532B2/en active Active
-
2024
- 2024-12-05 US US18/970,690 patent/US20250223355A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20201285T1 (hr) | Reagensi sirp-alfa visokog afiniteta | |
| AU2018264321A1 (en) | Bispecific recombinant protein and use thereof | |
| MX336623B (es) | Peptidos penetradores de las celulas y usos de los mismos. | |
| CN103819559B (zh) | 一种抗间皮素纳米抗体及其编码基因和该纳米抗体的用途 | |
| IL275497B (en) | Serum albumin-binding fibronectin type iii domains | |
| FI4073098T3 (fi) | Ultrapitkävaikutteiset insuliini-Fc-fuusioproteiinit ja niiden käyttömenetelmät | |
| BR112012033406A2 (pt) | anticorpo para diagnóstico e/ou prognóstico de câncer | |
| BRPI0607315A2 (pt) | polinucleotìdeo isolado, vetor de expressão, composição, método de produzir uma molécula de ligação de antìgeno, molécula de ligação de antìgeno e o uso da mesma-, método para detectar in vivo ou in vitro a presença de egfr em uma amostra, célula hospedeira engendrada, composição farmacêutica e o uso da mesma | |
| CN106414482A (zh) | T细胞受体 | |
| MX2019009382A (es) | Anticuerpo anti-humano de anexina a1. | |
| CN105037547B (zh) | 基于afp抗原的afp纳米抗体a18 | |
| RU2016126425A (ru) | Пептиды, связывающие cd44 | |
| CN108503691A (zh) | 一种人pd-l1蛋白高亲和性肽及其应用 | |
| CN105037546B (zh) | 基于afp抗原的afp纳米抗体a65 | |
| CN102634487B (zh) | Gpc3单克隆抗体杂交瘤细胞株8g6及其制备方法和应用 | |
| CN104650185A (zh) | 一条与猪瘟e0蛋白相结合的多肽序列及其应用 | |
| CN102671185A (zh) | 少棘蜈蚣多肽毒素omega-SLPTX-Ssm1a的应用 | |
| CN112048018A (zh) | 一种嵌合t细胞生长因子及其应用 | |
| CN110669109A (zh) | 一种酶联标签短肽及其应用 | |
| CN103772501A (zh) | Vegf抗体及其制备方法和用途 | |
| CN102250217A (zh) | 华南雨蛙促皮肤损伤修复多肽及其基因和应用 | |
| Minamihata et al. | Photosensitizer and polycationic peptide-labeled streptavidin as a nano-carrier for light-controlled protein transduction | |
| JPWO2020181145A5 (hr) | ||
| CN106957370B (zh) | 一种可在肿瘤细胞内引发毒性的多肽 | |
| BRPI0910513B8 (pt) | uso de pelo menos um polipeptídeo, método para a detecção de câncer de mama e leucemia in vitro, e reagente para a detecção de câncer de mama e leucemia |